What next for the environmental legislative regime under The Retained EU Law (Revocation and Reform) Bill 2022?
Applying for registration in the new Register of Overseas Entities
Mobile gaming MA trends and predictions
From Open Banking to Open Finance FiDA
Internal investigations: when does privilege apply?
Real Estate Focus: November 2023
Real Estate Focus: June 2022
Taskforce on Nature-related Financial Disclosures publishes draft sector-specific guidance
The outlook for banking sector M&A in 2023
Single-use plastics: What will be banned?
Insurance focus: Key developments in the insurance sector in the Middle East – second edition
Foreign Subsidy Scrutiny in Merger Review – the EU and US on Parallel Tracks?
What is a “ship”?
ATAD 3: The Unshell Directive | Where are we now and what are the next steps?
Real Estate Focus – August 2023
Navigating the twilight: The Hong Kong courts follow recent English authority on the distinction between jurisdiction and admissibility
If an application for reserved matters approval has been submitted within the 3 year period and refused, can a further reserved matters application be made outside the 3 year period?
Working group to update pharmaceutical merger review in the US, Canada, UK and Europe | Knowledge | Global law firm | Norton Rose Fulbright